Oramed Pharmaceuticals (ORMP) EBT (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly EBT came in at $49.4 million in Q1 2026, up 800.48% YoY from $5.5 million in Q1 2025, and up 404.64% on a QoQ basis from $9.8 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) EBT (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of EBT data on file, last reported at $49.4 million in Q1 2026.
- Quarterly EBT rose 800.48% year-over-year to $49.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $131.8 million (up 637.79% YoY) and the FY2025 annual result came in at $75.3 million, up 573.14% from the prior year.
- EBT grew to $49.4 million in Q1 2026, from $9.8 million in the prior quarter.
- In the past five years, EBT ranged from a high of $59.5 million in Q3 2025 to a low of -$18.5 million in Q3 2024.
- A 5-year average of $4.2 million and a median of -$3.3 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT jumped 925.44% — and 2025, when it tumbled 560.1%.
- Tracing ORMP's EBT over 5 years: stood at -$12.3 million in 2022, then surged by 208.49% to $13.3 million in 2023, then sank by 173.58% to -$9.8 million in 2024, then surged by 200.14% to $9.8 million in 2025, then surged by 404.64% to $49.4 million in 2026.
- The last three EBT figures came in at $49.4 million (Q1 2026), $9.8 million (Q4 2025), and $59.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | 101.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.59 Mn |
| Mar 31, 2026 | 49.44 Mn |
| Dec 31, 2025 | 9.80 Mn |
| Sep 30, 2025 | 59.45 Mn |
| Jun 30, 2025 | 13.13 Mn |
| Mar 31, 2025 | -7.06 Mn |
| Dec 31, 2024 | -9.78 Mn |
| Sep 30, 2024 | -18.51 Mn |
| Jun 30, 2024 | 10.84 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 13.30 Mn |
| Sep 30, 2023 | -3.28 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -3.62 Mn |
| Dec 31, 2022 | -12.26 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -12.10 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Aug 31, 2021 | -22.99 Mn |
| Nov 30, 2019 | -2.45 Mn |